These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 14510178)

  • 1. Breast cancer biomarkers and molecular medicine.
    Ross JS; Linette GP; Stec J; Clark E; Ayers M; Leschly N; Symmans WF; Hortobagyi GN; Pusztai L
    Expert Rev Mol Diagn; 2003 Sep; 3(5):573-85. PubMed ID: 14510178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cancer biomarkers and molecular medicine: part II.
    Ross JS; Linette GP; Stec J; Clark E; Ayers M; Leschly N; Symmans WF; Hortobagyi GN; Pusztai L
    Expert Rev Mol Diagn; 2004 Mar; 4(2):169-88. PubMed ID: 14995904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER-2/neu expression in primary and metastatic breast cancer.
    Lower EE; Glass E; Blau R; Harman S
    Breast Cancer Res Treat; 2009 Jan; 113(2):301-6. PubMed ID: 18273700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of HER-2/neu (erbB-2) status in breast cancer: from bench to bedside.
    Hanna W; Kahn HJ; Trudeau M
    Mod Pathol; 1999 Aug; 12(8):827-34. PubMed ID: 10463486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2/neu role in breast cancer: from a prognostic foe to a predictive friend.
    Ferretti G; Felici A; Papaldo P; Fabi A; Cognetti F
    Curr Opin Obstet Gynecol; 2007 Feb; 19(1):56-62. PubMed ID: 17218853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapy for cancer: the HER-2/neu and Herceptin story.
    Ross JS; Gray GS
    Clin Leadersh Manag Rev; 2003; 17(6):333-40. PubMed ID: 14692077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
    Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and predictive value of HER2/neu oncogene in breast cancer.
    Masood S; Bui MM
    Microsc Res Tech; 2002 Oct; 59(2):102-8. PubMed ID: 12373720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers for breast cancer.
    Beenken SW; Bland KI
    Minerva Chir; 2002 Aug; 57(4):437-48. PubMed ID: 12145573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
    Menendez JA; Vellon L; Lupu R
    Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Both t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancers.
    Hamel S; Bouchard A; Ferrario C; Hassan S; Aguilar-Mahecha A; Buchanan M; Quenneville L; Miller W; Basik M
    Breast Cancer Res Treat; 2010 Feb; 120(1):47-57. PubMed ID: 19301121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple biomarkers in molecular oncology. II. Molecular diagnostics applications in breast cancer management.
    Malinowski DP
    Expert Rev Mol Diagn; 2007 May; 7(3):269-80. PubMed ID: 17489734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer.
    Sachdev JC; Jahanzeb M
    Clin Breast Cancer; 2012 Feb; 12(1):19-29. PubMed ID: 21903480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy.
    Ross JS
    Drug News Perspect; 2009 Mar; 22(2):93-106. PubMed ID: 19330168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [HER-2 diagnostics].
    Bánkfalvi A
    Magy Onkol; 2002; 46(1):11-5. PubMed ID: 12050677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hidden HER-2/neu-positive breast cancer: how to maximize detection.
    Carney WP
    IDrugs; 2009 Apr; 12(4):238-42. PubMed ID: 19350468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNAs in breast cancer pathogenesis.
    Götte M
    Minerva Ginecol; 2010 Dec; 62(6):559-71. PubMed ID: 21079577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER-2/neu gene product in serum--an oncoprotein in the diagnosis and therapy of breast carcinoma.
    Schulze G
    Anticancer Res; 2003; 23(2A):1007-10. PubMed ID: 12820339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Quality assured HER2 analysis in breast cancer. Important therapeutic predictive and prognostic factor].
    Fernö M; Haglund M; Bendahl PO; Olsson H; Rydén L
    Lakartidningen; 2008 Aug 6-19; 105(32-33):2181-4. PubMed ID: 18780693
    [No Abstract]   [Full Text] [Related]  

  • 20. Prediction of recurrence for advanced breast cancer. Traditional and contemporary pathologic and molecular markers.
    Masood S
    Surg Oncol Clin N Am; 1995 Oct; 4(4):601-32. PubMed ID: 8535901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.